UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 2, 2026
United Therapeutics Corporation
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-26301 | 52-1984749 | ||
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| 1000 Spring Street | ||
| Silver Spring, MD | 20910 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.01 per share | UTHR | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure
On March 2, 2026, United Therapeutics Corporation (the “Company”) issued a press release announcing positive results of the ADVANCE OUTCOMES clinical study of ralinepag in patients with pulmonary arterial hypertension. The press release is attached as Exhibits 99.1 and is incorporated herein by reference.
As disclosed in the press release, the Company intends to host a webcast presentation to discuss the ADVANCE OUTCOMES results at 8:30 a.m. Eastern Time on March 2, 2026. The presentation will include the slides furnished as Exhibit 99.2 hereto and incorporated herein by reference. These slides will also be posted to the Company’s website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.
Item 9.01. Exhibits
| (d) Exhibits | |||
| Exhibit No. | Description of Exhibit | ||
| 99.1 | Press Presentation dated March 2, 2026 | ||
| 99.2 | Investor Presentation dated March 2, 2026 | ||
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | ||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | ||
| Dated: March 2, 2026 | By: | /s/ Paul A. Mahon |
| Name: | Paul A. Mahon | |
| Title: | General Counsel | |
3